Skip to main content
Premium Trial:

Request an Annual Quote

OvaGene Inks Deal for miRNA Biomarkers for Cancer Drug Response

Premium

OvaGene said this week that it has signed a licensing and collaboration agreement with the Moffitt Cancer Center to develop microRNAs as biomarkers for cancer drug response.

OvaGene said it now has the exclusive rights to to develop and commercialize assays based on miRNAs validated by Moffitt researcher Johnathan Lancaster. The company said it would initially focus on a test that can predict an ovarian cancer patient's response to treatment, and expects to have a product ready for market in 18 to 24 months.

The firm said it would create additional assays to predict drug response to other gynecologic cancers in the future.

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.